Across TCGA pan-cancer cohorts, OR5L2 Mutation is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated OR5L2 data layer compared with 6 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher OR5L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR5L2 expression acts as an unfavorable survival marker.
HNSC, CHOL, and LUSC are the cancer types where OR5L2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.